Leap Therapeutics logo

Leap Therapeutics Share Price Today

(NASDAQ: LPTX)

Leap Therapeutics share price is $0.43 & ₹37.40 as on 6 Mar 2025, 2.30 'hrs' IST

$0.43

-0.01

(-1.45%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Leap Therapeutics share price in Dollar and Rupees. Guide to invest in Leap Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Leap Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Leap Therapeutics share price movements

  • Today's Low: $0.42
    Today's High: $0.44

    Day's Volatility :3.76%

  • 52 Weeks Low: $0.42
    52 Weeks High: $4.79

    52 Weeks Volatility :91.31%

Leap Therapeutics (LPTX) Returns

PeriodLeap Therapeutics IncIndex (Russel 2000)
3 Months
-85.44%
0.0%
6 Months
-85.09%
0.0%
1 Year
-81.55%
0.0%
3 Years
-97.5%
-11.6%

Leap Therapeutics (LPTX) Key Statistics

in dollars & INR

Previous Close
$0.4354
Open
$0.4303
Today's High
$0.441
Today's Low
$0.4244
Market Capitalization
$16.2M
Today's Volume
$4.0K
52 Week High
$4.79
52 Week Low
$0.4163
Revenue TTM
$375.0K
EBITDA
$-68.8M
Earnings Per Share (EPS)
$-1.64
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-107.18%

How to invest in Leap Therapeutics Stock (LPTX) from India?

It is very easy for Indian residents to invest directly in Leap Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Leap Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Leap Therapeutics or LPTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Leap Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Leap Therapeutics shares which would translate to 2.023 fractional shares of Leap Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Leap Therapeutics, in just a few clicks!

Returns in Leap Therapeutics (LPTX) for Indian investors in Rupees

The Leap Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Leap Therapeutics investment value today

Current value as on today

₹23,183

Returns

₹76,817

(-76.82%)

Returns from Leap Therapeutics Stock

₹81,780 (-81.78%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Leap Therapeutics (LPTX)

28%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Leap Therapeutics Stock from India on INDmoney has increased by 28% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Leap Therapeutics

  • Samsara BioCapital, LLC

    6.37%

  • Point72 Asset Management, L.P.

    3.65%

  • 683 Capital Management LLC

    3.52%

  • Rock Springs Capital Management LP

    3.31%

  • Vanguard Group Inc

    3.11%

  • Baker Bros Advisors LP

    3.06%

Analyst Recommendation on Leap Therapeutics

Buy

    90%Buy

    10%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Leap Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Leap Therapeutics Stock (LPTX)

What analysts predicted

Upside of 597.67%

Target:

$3.00

Current:

$0.43

Insights on Leap Therapeutics Stock (Ticker Symbol: LPTX)

  • Price Movement

    In the last 3 months, LPTX stock has moved down by -85.4%
  • LPTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 145.6%
  • LPTX vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 145.3%
  • Price to Sales

    ForLPTX every $1 of sales, investors are willing to pay $145.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

Leap Therapeutics Technicals Summary

Sell

Neutral

Buy

Leap Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Leap Therapeutics (LPTX) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Leap Therapeutics Inc logo
-16.81%
-85.09%
-81.55%
-97.5%
-98.14%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Leap Therapeutics Inc logo
NA
NA
0.75
-1.84
-1.07
-0.58
NA
1.28
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Leap Therapeutics Inc logo
Buy
$16.2M
-98.14%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Organization
Leap Therapeutics
Employees
54
CEO
Mr. Douglas E. Onsi J.D.
Industry
Health Technology

Management People of Leap Therapeutics

NameTitle
Mr. Douglas E. Onsi J.D.
CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Mr. Augustine J. Lawlor
Chief Operating Officer
Dr. Cynthia A. Sirard M.D.
Chief Medical Officer
Dr. Jason S. Baum Ph.D.
Chief Scientific Officer
Mr. Mark O'Mahony
Chief Manufacturing Officer
Ms. Christine M. Granfield
VP and Head of Regulatory Affairs & Quality

Important FAQs about investing in LPTX Stock from India :

What is Leap Therapeutics share price today?

Leap Therapeutics share price today stands at $0.43, Open: $0.43 ; Previous Close: $0.44 ; High: $0.44 ; Low: $0.42 ; 52 Week High: $4.79 ; 52 Week Low: $0.42.

The stock opens at $0.43, after a previous close of $0.44. The stock reached a daily high of $0.44 and a low of $0.42, with a 52-week high of $4.79 and a 52-week low of $0.42.

Can Indians buy Leap Therapeutics shares?

Yes, Indians can invest in the Leap Therapeutics (LPTX) from India.

With INDmoney, you can buy Leap Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Leap Therapeutics at zero transaction cost.

How can I buy Leap Therapeutics shares from India?

It is very easy to buy Leap Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Leap Therapeutics (LPTX) be purchased?

Yes, you can buy fractional shares of Leap Therapeutics with INDmoney app.

What are the documents required to start investing in Leap Therapeutics stocks?

To start investing in Leap Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Leap Therapeutics Stock (LPTX)?

Today’s highest price of Leap Therapeutics (LPTX) is $0.44.

Today’s lowest price of Leap Therapeutics (LPTX) is $0.42.

What is today's market capitalisation of Leap Therapeutics?

Today's market capitalisation of Leap Therapeutics LPTX is 16.2M

What is the 52 Week High and Low Range of Leap Therapeutics Stock (LPTX)?

  • 52 Week High

    $4.79

  • 52 Week Low

    $0.42

What are the historical returns of Leap Therapeutics (LPTX)?

  • 1 Month Returns

    -16.81%

  • 3 Months Returns

    -85.09%

  • 1 Year Returns

    -81.55%

  • 5 Years Returns

    -98.14%

Who is the Chief Executive Officer (CEO) of Leap Therapeutics ?

Mr. Douglas E. Onsi J.D. is the current Chief Executive Officer (CEO) of Leap Therapeutics.